BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 15914228)

  • 1. Universal influenza A vaccine: optimization of M2-based constructs.
    De Filette M; Min Jou W; Birkett A; Lyons K; Schultz B; Tonkyro A; Resch S; Fiers W
    Virology; 2005 Jun; 337(1):149-61. PubMed ID: 15914228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A "universal" human influenza A vaccine.
    Fiers W; De Filette M; Birkett A; Neirynck S; Min Jou W
    Virus Res; 2004 Jul; 103(1-2):173-6. PubMed ID: 15163506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
    De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
    Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
    Liu W; Zou P; Chen YH
    Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A universal influenza A vaccine based on the extracellular domain of the M2 protein.
    Neirynck S; Deroo T; Saelens X; Vanlandschoot P; Jou WM; Fiers W
    Nat Med; 1999 Oct; 5(10):1157-63. PubMed ID: 10502819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M2e-based universal influenza A vaccine.
    Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
    Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.
    Ravin NV; Kotlyarov RY; Mardanova ES; Kuprianov VV; Migunov AI; Stepanova LA; Tsybalova LM; Kiselev OI; Skryabin KG
    Biochemistry (Mosc); 2012 Jan; 77(1):33-40. PubMed ID: 22339631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M; Ramne A; Birkett A; Lycke N; Löwenadler B; Min Jou W; Saelens X; Fiers W
    Vaccine; 2006 Jan; 24(5):544-51. PubMed ID: 16169634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.
    Zou P; Liu W; Chen YH
    Int Immunopharmacol; 2005 Apr; 5(4):631-5. PubMed ID: 15710332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein.
    Wang R; Song A; Levin J; Dennis D; Zhang NJ; Yoshida H; Koriazova L; Madura L; Shapiro L; Matsumoto A; Yoshida H; Mikayama T; Kubo RT; Sarawar S; Cheroutre H; Kato S
    Antiviral Res; 2008 Nov; 80(2):168-77. PubMed ID: 18598723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.